Tekturna (Aliskiren Hemifumarate) Patent Expiration, LOE Window & CMS Spending
Tekturna (Aliskiren Hemifumarate) by Lxo Ireland Designated Activity: FDA Orange Book LOE 2026-08-19, 1 AB generics, $928K 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Lxo Ireland Designated Activity |
| FDA Application & Pathway | N021985 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2026-08-19 |
| Orange Book Patents (*PED Extensions) | 2 patents (1 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $928K |
| 2024 Medicare Part D Spend | $868K |
| 2024 Medicaid Spend | $60K |
| Reported Wholesale Price Change (CA SB 17) | 8 WAC filings (max 29.5% 2-yr change) |